S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   289.63 (-5.40%)
AAPL   140.50 (-5.86%)
MSFT   253.50 (-4.99%)
FB   192.10 (-5.19%)
GOOGL   2,230.02 (-4.27%)
AMZN   2,129.54 (-7.71%)
TSLA   708.56 (-6.97%)
NVDA   168.13 (-7.50%)
BABA   87.24 (-5.16%)
NIO   15.86 (-4.63%)
AMD   95.96 (-6.35%)
CGC   5.59 (-5.09%)
MU   70.92 (-4.78%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.77 (-5.62%)
DIS   104.00 (-4.27%)
AMC   12.73 (-1.32%)
PFE   50.41 (-1.81%)
PYPL   77.09 (-3.34%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   289.63 (-5.40%)
AAPL   140.50 (-5.86%)
MSFT   253.50 (-4.99%)
FB   192.10 (-5.19%)
GOOGL   2,230.02 (-4.27%)
AMZN   2,129.54 (-7.71%)
TSLA   708.56 (-6.97%)
NVDA   168.13 (-7.50%)
BABA   87.24 (-5.16%)
NIO   15.86 (-4.63%)
AMD   95.96 (-6.35%)
CGC   5.59 (-5.09%)
MU   70.92 (-4.78%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.77 (-5.62%)
DIS   104.00 (-4.27%)
AMC   12.73 (-1.32%)
PFE   50.41 (-1.81%)
PYPL   77.09 (-3.34%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   289.63 (-5.40%)
AAPL   140.50 (-5.86%)
MSFT   253.50 (-4.99%)
FB   192.10 (-5.19%)
GOOGL   2,230.02 (-4.27%)
AMZN   2,129.54 (-7.71%)
TSLA   708.56 (-6.97%)
NVDA   168.13 (-7.50%)
BABA   87.24 (-5.16%)
NIO   15.86 (-4.63%)
AMD   95.96 (-6.35%)
CGC   5.59 (-5.09%)
MU   70.92 (-4.78%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.77 (-5.62%)
DIS   104.00 (-4.27%)
AMC   12.73 (-1.32%)
PFE   50.41 (-1.81%)
PYPL   77.09 (-3.34%)
NFLX   177.18 (-7.02%)
S&P 500   3,923.68 (-4.04%)
DOW   31,490.07 (-3.57%)
QQQ   289.63 (-5.40%)
AAPL   140.50 (-5.86%)
MSFT   253.50 (-4.99%)
FB   192.10 (-5.19%)
GOOGL   2,230.02 (-4.27%)
AMZN   2,129.54 (-7.71%)
TSLA   708.56 (-6.97%)
NVDA   168.13 (-7.50%)
BABA   87.24 (-5.16%)
NIO   15.86 (-4.63%)
AMD   95.96 (-6.35%)
CGC   5.59 (-5.09%)
MU   70.92 (-4.78%)
T   20.25 (-1.56%)
GE   75.26 (-1.49%)
F   12.77 (-5.62%)
DIS   104.00 (-4.27%)
AMC   12.73 (-1.32%)
PFE   50.41 (-1.81%)
PYPL   77.09 (-3.34%)
NFLX   177.18 (-7.02%)
OTCMKTS:CRTPF

Cardiol Therapeutics (CRTPF) Stock Forecast, Price & News

$1.27
+0.14 (+12.39%)
(As of 05/17/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.16
$1.27
50-Day Range
$1.03
$2.05
52-Week Range
$1.48
$4.19
Volume
120,690 shs
Average Volume
67,097 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
30 days | 90 days | 365 days | Advanced Chart
Receive CRTPF News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Cardiol Therapeutics logo

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Drug Manufacturers—Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:CRTPF
CIK
N/A
Fax
N/A
Employees
6
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Optionable
Not Optionable

MarketRank

Overall MarketRank

0.85 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -













Cardiol Therapeutics (OTCMKTS:CRTPF) Frequently Asked Questions

Is Cardiol Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardiol Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Cardiol Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRTPF, but not buy additional shares or sell existing shares.
View analyst ratings for Cardiol Therapeutics
or view top-rated stocks.

Who are Cardiol Therapeutics' key executives?
Cardiol Therapeutics' management team includes the following people:
  • David G. Elsley, President, Chief Executive Officer & Director
  • Bernard Ching-Bing Lim, Chief Operating Officer
  • Christopher J. Waddick, Chief Financial Officer & Secretary
  • Anthony E. Bolton, Director of Research
  • Andrew Hamer, Chief Medical Officer
What is Cardiol Therapeutics' stock symbol?

Cardiol Therapeutics trades on the OTCMKTS under the ticker symbol "CRTPF."

How do I buy shares of Cardiol Therapeutics?

Shares of CRTPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiol Therapeutics' stock price today?

One share of CRTPF stock can currently be purchased for approximately $1.27.

How many employees does Cardiol Therapeutics have?

Cardiol Therapeutics employs 6 workers across the globe.

What is Cardiol Therapeutics' official website?

The official website for Cardiol Therapeutics is www.cardiolrx.com.

How can I contact Cardiol Therapeutics?

The company can be reached via phone at (289) 910-0850.

This page was last updated on 5/18/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.